Onconetix Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Ralph Schiess

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership6.0%
Management average tenure1.7yrs
Board average tenure1.9yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation

Jan 24
Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation

Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia

Oct 11

Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot

Aug 17

Blue Water Vaccines in pact to study Alzheimer’s vaccine

Jul 20

Blue Water Vaccines: Estimates And Expectations

May 17

CEO

Ralph Schiess (45 yo)

less than a year

Tenure

Dr. Ralph Schiess, Ph D., serves as Chief Science Officer at Onconetix, Inc. since December 15, 2023 and serves as its Interim Chief Executive Officer since January 12, 2024. He Co-founded ProteoMediX AG i...


Leadership Team

NamePositionTenureCompensationOwnership
Ralph Schiess
Interim CEO & Chief Science Officerless than a yearno data5.98%
$ 168.6k
Karina Fedasz
Interim Chief Financial Officerless than a yearno datano data
Brian Price
Head of Technology Strategy4.3yrsUS$126.48kno data
Andrew Skibo
Global Head of Biologics Operations3.5yrsno datano data
Theodore Yoho
Head of Business Development3.5yrsno datano data
Ali Fattom
Head of Science & Discovery2.3yrsno datano data
Jay Newmark
Chief Medical Officer1.7yrsno datano data
Christian Bruhlmann
Chief Strategy Officer & GM of Europeless than a yearno data5.23%
$ 147.5k
Donald Very
Senior VP of Commercial Research & Developmentno datano datano data
Christian Bruehlmann
less than a yearno datano data

1.7yrs

Average Tenure

47yo

Average Age

Experienced Management: ONCO's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
John Rice
Member of Scientific Advisory Boardno datano datano data
Thomas Meier
Independent Directorless than a yearno data0.040%
$ 1.1k
James Sapirstein
Non Executive Chairman & Lead Independent Director2.8yrsUS$182.12k0.042%
$ 1.2k
Ajit Singh
Independent Directorless than a yearno data0.041%
$ 1.2k
Sunetra Gupta
Member of Scientific Advisory Boardno datano datano data
Simon Tarsh
Independent Director2.3yrsUS$112.62k0.042%
$ 1.2k
Timothy Ramdeen
Independent Non-Executive Director1.9yrsUS$82.67k0.042%
$ 1.2k

1.9yrs

Average Tenure

62.5yo

Average Age

Experienced Board: ONCO's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 17:15
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Onconetix, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vernon BernardinoH.C. Wainwright & Co.
Jason McCarthyMaxim Group